FORMOTÉROL

EUEMA:by formoterol fumarate dihydrate AU:B3 R03AC13(WHO)R03CC15(WHO) AU:S4(Prescription only)NZ: Prescription onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) (RR,SS)-N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl) propan-2-ylamino]ethyl] phenyl]formamide 73573-87-2Y 30835443034756 3465 DB00983Y 2340731Y 5ZZ84GCW8B D07990Y CHEBI:408174Y ChEMBL1363Y DTXSID20860603 DTXSID1023077, DTXSID20860603 Interactive image O=CNc1cc(ccc1O)[C@@H](O)CN[C@H](C)Cc2ccc(OC)cc2 InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1YKey:BPZSYCZIITTYBL-YJYMSZOUSA-NY Formoterol, also known aseformoterol, is along-acting β2agonist(LABA) used as abronchodilatorin the management ofasthmaandchronic obstructive pulmonary disease(COPD). Formoterol has an extended duration of action (up to 12 h) compared to short-acting β2agonists such assalbutamol(albuterol), which are effective for 4 h to 6 h. Formoterol has a relatively rapid onset of action compared to other LABAs, and is effective within 2-3 minutes.The 2022Global Initiative for Asthmareportrecommends a combination formoterol/inhaled corticosteroid inhaler as both a preventer and reliever treatment for asthma in adults. In children, a short-acting β2adrenergic agonist (e.g.,salbutamol) is still recommended. It was patented in 1972 and came into medical use in 1998.It is available as ageneric medication.It is also marketed in the combination formulationsbudesonide/formoterolandmometasone/formoterol.